secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001193125-24-024112
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA identifies deficiencies in Vanda's sNDA for HETLIOZ insomnia; Vanda alleges FDCA violation
--------------------------------------------------------------------------------

- FDA notified Vanda on Feb 4, 2024 of deficiencies in sNDA for HETLIOZ (tasimelteon) for insomnia; no details disclosed.
- Vanda claims FDA violated FDCA by missing statutory deadline of Oct 31, 2023, to approve or provide a hearing.
- sNDA submitted May 4, 2023; PDUFA target date was March 4, 2024; deficiencies preclude labeling discussions.
- Vanda is also challenging FDA approvals of generic HETLIOZ, which have been marketed since 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524024112/0001193125-24-024112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524024112/d772316d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-024112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer